Exagen (NASDAQ:XGN) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.26) by 23.08 percent. This is a 35.48 percent increase over losses of $(0.31) per share from the same period last year. The company reported quarterly sales of $13.65 million which missed the analyst consensus estimate of $13.85 million by 1.39 percent. This is a 0.80 percent decrease over sales of $13.77 million the same period last year.